Focal Segmental Glomerulosclerosis Market – Regional Analysis
On the basis of region, the global focal segmental glomerulosclerosis market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to dominate the FSGS market due to high prevalence of FSGS along with chronic kidney diseases. For instance, According to an annual data report by the U.S. Renal Data System 2017, the overall burden of kidney disease, kidney failure with dialysis, and kidney transplantation is highest in U.S., thus driving the growth of the focal segmental glomerulosclerosis market.
Asia Pacific region is expected to witness significant growth in market due to collaboration agreements and partnerships among various players. For instance, Oraxion Therapeutics, Inc., a subsidiary of Indian company Aten Porus, is undergoing preclinical and efficacy study of the drug, ORX-301, which can be used in the treatment of FSGS. In February 2018, Oraxion Therapeutics, Inc., entered into an Option Agreement with the U.S-based Biopharmaceutical Company and under this agreement, U.S. based company gets exclusive rights for further clinical studies and license of this drug in the U.S.
Focal Segmental Glomerulosclerosis Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients